Because angiotensin-converting enzyme (ACE) activity is implicated widely in biological systems, we aimed to identify its novel quantitative trait loci for the purposes of understanding ACE activity regulation and pharmacogenetics relating to ACE inhibitor (ACEI). We performed a two-stage genome-wide association study: (1) from 400 young-onset hypertension (YOH) subjects and (2) a confirmation study with an additional 623 YOH subjects. In the first stage, eight single nucleotide polymorphisms (SNPs) of the ACE structural gene and one SNP of ABO genes were significantly associated with ACE activity. SNP rs4343 in exon17 near the well-known insertion/deletion polymorphism had the strongest association. We confirmed in the second stage that three SNPs: rs4343 in ACE gene (P ¼ 3.0 Â 10 À25 ), rs495828 (P ¼ 3.5 Â 10 À8 ) and rs8176746 (P ¼ 9.3 Â 10 À5 ) in ABO gene were significantly associated with ACE activity. We further replicated the association between ABO genotype/blood types and ACE activity in an independent YOH family study (428 hypertension pedigrees), and showed a potential differential blood pressure response to ACEI in subjects with varied numbers of ACE-activity-raising alleles. These findings may broaden our understanding of the mechanisms controlling ACE activity and advance our pharmacogenetic knowledge on ACEI.
Introduction
The genome-wide association studies (GWAS) for complex diseases are gaining more attention in the wake of the publication in 2007 on seven complex diseases by the Wellcome Trust Case Control Consortium. 1 Although GWAS on large-scale samples has been noteworthy to reveal novel susceptibility loci for a variety of common diseases, 2 most studies identified genes with small-to-moderate effects on such challenging diseases. 3, 4 This phenomenon is likely due to the heterogeneous nature of most complex diseases. Therefore, an efficient approach would be to dissect complex diseases into more homogeneous endo-or intermediate phenotypes that tend to have greater heritability than the original phenotype. 5, 6 It has been proposed that this approach, by focusing on a narrower disease facet, could help uncover the genes related to the subsets of the original complex disease and contribute to the understanding the disease etiology.
Angiotensin-converting enzyme (ACE) is a key enzyme of the famous renin-angiotensin-aldosterone system and is pivotal for electrolyte balance and blood pressure regulation, 7, 8 which converts angiotensin I to angiotensin II, a potent vasoconstrictor and degrades bradykinin, a strong vasodilator. Angiotensin II also contributes to other biological processes either through direct pathological effects on tissues, including vascular remodeling and inflammation or through indirect action on nitric oxide bioavailability and its consequences. 9 Furthermore, the ACE genetic variation, in particular Alu insertion/deletion polymorphism in intron 16, has been associated with the risk of a wide range of clinical outcomes including cardiovascular diseases, response to ACE inhibitor (ACEI) therapy, diabetic nephropathy, muscle performance, longevity and Alzheimer's disease, 10, 11 although the results are conflicting. Strong evidence exists for an association between insertion/deletion polymorphism and plasma ACE activity with increased level among those with the D allele. 12 Therefore, the ACE activity represents an upstream and internal facet of hypertension, which has a reasonably high heritability (estimated range: 0.2-0.7) 12, 13 and small intraindividual variations. 14 The ACE activity consequently falls into socalled 'good intermediate phenotype' category described by Pan et al. 6 and others for discovering variants with potential involvement in blood pressure regulation, cardiovascular function and other biological processes. We performed a GWAS by using 560 168 single nucleotide polymorphism (SNP) genotypes derived from the Illumina HumanHap550 SNP chip in 400 subjects with young-onset hypertension (YOH) to identify the quantitative trait loci associated with the ACE activity and to evaluate the efficacy of the GWAS for mapping up the genes on a highly heritable trait. It is observed that, in addition to the ACE, the gene ABO was significantly associated with the ACE activity. We also examined the association between the ABO blood types and the ACE activity and compared blood pressure trends (as surrogate of responses to pharmaceuticals) with varied numbers of ACE-activity-raising alleles between users and nonusers of ACEI. Any information thus secured on the genetic determinants of ACE activity after further replication by others, in our opinion, could be applied clinically to facilitate both the categorization and the treatment of the ACE-linked diseases.
Materials and methods

GWAS on the quantitative ACE activity trait
We performed a two-stage GWAS to search the genes/loci that influence ACE activity. A total of 1023 hypertensive subjects were recruited by the Academia Sinica MultiCentered Young-Onset Hypertension (AS-YOH) Genetic Study. A total of 400 hypertensive subjects were included at the initial GWAS stage, and 623 hypertensive subjects were included in the confirmatory stage. There were six inclusion criteria for hypertensive subjects: (1) systolic blood pressure (SBP) X140 mm Hg and/or diastolic blood pressure (DBP) X90 mm Hg over a 2-month period or for those who were on antihypertensive medications, SBP/DBP X120/ 80 mm Hg in two consecutive visits within 2 months; (2) age was between 20 and 51 at first diagnosis of hypertension; (3) no secondary causes of hypertension such as chronic renal disease, renal arterial stenosis, primary aldosteronism, coarctation of the aorta, thyroid disorders, Cushing syndrome and pheochromocytoma confirmed through extensive clinical examinations including blood chemistry, renal function tests, endocrine examination and abdominal sonogram; (4) fasting glucose level was less than 126 mg per 100 ml; (5) body mass index was less than 35 kg m À2 and (6) self-reported Han Chinese ethnicity in more than two generations.
Data collection was carried out according to standardized protocols. Blood pressure and pulse were measured following the protocol established for the Nutrition and Health Survey in Taiwan. 15 The serum ACE activity (IU l À1 , nmol min À1 ml
À1
) was measured on heparinized plasma prepared from fasting blood samples (10-12 h fast), using the spectrophotometric method (ACEcolor; Fujirebio Inc., Tokyo, Japan). 16 Intra-assay coefficient of variance calculated from duplicated samples was 4.0%. In addition, the data on socio-demographic factors, the smoking and drinking habits, the past medical history and the current medications were acquired through interview. Such a multicenter study has been approved by the human investigation committee of Academia Sinica. All the informed consent was taken from all participants during their initial clinic visit.
An independent YOH family study for replicating the relation between ABO blood types and ACE activity Data were gathered from 464 hypertensive subjects from YOH family genetic study. 17 This family study has been approved by the Human Investigation Committee of the Institute of Biomedical Sciences, Academia Sinica. The informed consent was also taken from each participant.
The hypertension probands for this study came from four community hospitals: namely, the Chu-Tung Department of Health Hospital, the Tao Yuan Hospital Department of Health, the Li-Shin Hospital and the Min-Sheng Hospital. The inclusion criteria for hypertensive patients were basically the same as the AS-YOH Genetic Study except that the age at first diagnosis of hypertension was less than 40 in the family study. Most subjects of this study provided selfreported blood type information. For subjects who did not provide the information, the blood types were determined by a commercial kit (Gamma Biologicals, Houston, TX, USA). According to Blumenfeld and Patnaik, 18 the rs498528 is a good surrogate for A antigen allele and rs8176746 is for B antigen allele. We used these two SNPs to validate selfreported blood type. The A and B antigen alleles were highly consistent with blood type A and B (w 2 -test P ¼ 6.85 Â 10 À113 and 3.66 Â 10
À57
, respectively). The serum ACE activity was measured with the same method 16 described earlier.
ACE activity-SNPs association in normotensive subjects
To investigate the association between ACE activity and SNPs on ACE and ABO in normotensive subjects, we selected one normotensive subject from each YOH family described in the last section. A total of 282 normotensive subjects were placed in this replication in normotensives.
Genotyping methods
For the GWAS, genotyping experiments were performed by the deCODE genetics (Reykjavik, Iceland) with 400 leukocyte DNA samples using the Illumina Infinium II HumanHap550 SNP chips (Illumina, San Diego, CA, USA). We followed the Wellcome Trust Case Control Consortium criteria for quality control; 1 only those individuals were excluded in whom more than 3% of the required data was missing. The SNPs were excluded if they showed the HardyWeinberg equilibrium violation (Po1 Â 10 À7 ), the SNPs with call rates o95%, minor allele frequency o1%. Two SNPs with -log P-values more than 7 and one SNP which is a surrogate for B antigen allele and a nonsynonymous polymorphisms at the exon 7 of ABO gene (Àlog P ¼ 5.59) in the first stage was genotyped for the second-staged confirmation study and for the replication study using Sequenom platform (Sequenom MassARRAY System; San Diego, CA, USA) by the Academia Sinica National Genotyping Center (Taipei, Taiwan).
Statistical analysis
The ACE activity distribution was normalized by squarerooting the original value. We availed of the general linear model to associate ACE activity with genotype data, making adjustments for gender (0, 1), age and intake of ACEI (0, 1) in the first-, second-, third-stage and combined analyses. The genome-wide significant level was set less than 1 Â 10 À7 for multiple testing corrections 1 in the first stage.
To estimate the degree of genetic association explained by the chosen SNPs, we also performed a step-wise linear multiple regression model for the first-and second-stage data combined. An SNP was added to the model only if its P-value was less than 0.1. We determined the number of ACEactivity-raising alleles or genotypes by combining genotype information from the rs4343 (each G allele was given 1 point), the rs495828 (CC genotype was given 1 point), and the rs8176746 (CA or AA genotype was given 1 point) (4) for each individual. The general linear model with 'medication status (1, 0) Â the genetic score' term was used to compare the blood pressure trends (blood pressure value as the dependent variable) by the number of ACE-activityraising alleles/genotypes between those who take the ACEI alone and those who do not take any antihypertensive medication.
For the purpose of replicating the association between the ACE activity and the ABO blood types, we used the data from the independent hypertension family study to perform a regression analysis of the ACE activity in relation to ABO phenotype. Here the blood type O was set as the reference group. In the regression model, the age, gender (0, 1) and ACEI intake (0, 1) were included as covariates and the family ID was also adjusted by using a generalized estimating equation. 19 The same covariates were included for replicating ACE activity-SNP association in normotensive subjects, except that family ID was not adjusted, as only one subject per family was included.
Results
Study sample characteristics
There were no significant differences between subjects of the initial and the second stages (Table 1) regarding the gender distribution, the mean ACE activity, the mean SBP and the proportions of ACEI medication usage. Significant differences were noted for the mean age, body mass index and DBP values. For the latter two, the magnitudes of differences were very small.
GWAS findings
To reduce the potential confounding effects from the age, gender and ACEI intake, we adjusted for these factors in a linear regression analysis searching the quantitative trait loci influencing the ACE activity. As expected, we got the most significantly associated signals for eight SNPs of the ACE structural gene (located between the promoter and exon 24) with Àlog P-values ranging from 11.18 to 20.06 ( Figure 1 ). Particularly noteworthy is that the SNP rs4343 on exon17 had the highest Àlog P-value. We found that rs495828 on ABO gene was also significantly associated with ACE activity (Àlog P47; Figure 1 ). On the basis of GWAS results, we proceeded to use the SNPs with Àlog P-values 47 for the replication study. In this regard, the most significant SNPs in the same linkage disequilibrium block (rs4343 of ACE and rs495828 of ABO) or SNPs on coding region (rs8176746 of ABO) were picked. Three candidate SNPs were considered for the second-stage confirmatory study using an additional 623 hypertensive patients from the AS-YOH Genetic Study. All three SNPs were verified to be significantly associated with ACE activity ( New loci for ACE activity C-M Chung et al and rs8176746 at the exon 7 of ABO (P ¼ 9.30 Â 10 À5 ). After excluding the subjects taking ACEI, these three SNPs were still significantly associated with ACE activity to the similar degree (data not shown). Furthermore, these SNPs were significantly associated with ACE activity in the small-scale replication study with 282 normotensive subjects from the YOH family study ( Table 2) .
Variation of the ACE activity explained by ACE and ABO In the combined first and the second-stage analysis of the 1023 hypertensive patients, approximately 23.9% of the variance in the ACE activity was attributable to these three SNPs (rs4343, rs495828 and rs8176746). The SNP rs4343 in the ACE gene accounted for 16.2% of the total variance, whereas SNPs rs495828 and rs8176746 in the ABO gene reckoned an additional 4.9 and 2.8% of the total variance, respectively (Table 2) .
Independent samples to verify association between ABO blood types and the ACE activity Because of the strong associations were shown between ABO genotypes and the ACE activity, we investigated whether the Statistics corresponding to general linear model (GLM) testing association between genotypes and ACE activity after adjustment for age, gender (0, 1) and ACEI intake (0, 1) in the genome-wide association study comprising 400 subjects. Statistics corresponding to GLM testing association between genotypes and ACE activity after adjustment for age, gender (0, 1) and ACEI intake (0, 1) in the secondstage confirmatory study. e Statistical significance of GLM-based association between genotypes and ACE activity after adjustment for age, and gender in the third-stage confirmatory study comprising 282 additional normotensive subjects. f R 2 was obtained and ranked by forward stepwise regression in the first-and second-stage samples combined.
Figure 1 Illumina Human Hap550
SNPs associated with ACE activity using a genome-wide association study. Genes nearest to the SNPs are indicated at top. The general linear model was used to examine associations between SNPs and ACE activity after adjusting for age, gender (0, 1) and ACEI intake (0, 1), with the significance level set at Àlog P ¼ 7 (gray dotted line). The most significant SNPs in the same linkage disequilibrium (LD) block or SNPs on coding region in each gene were selected for a replication study. ACE, angiotensin-converting enzyme; ACEI, ACE inhibitor; SNP, single nucleotide polymorphism ABO blood types were associated with the ACE activity among the subjects from the YOH family study. Our data showed that people with blood type A had the lowest ACE activity and that those with type B had the highest. The mean ACE activity was much higher in people with only B antigen as compared with the blood type O subjects (P ¼ 2.3 Â 10 À10 ), and the mean ACE activity of the blood type A subjects was significantly lower than that of the blood type O (P ¼ 1.5 Â 10 À8 ). Also, the mean ACE activity of type AB was between those of type A and type B, but was not significantly different from that of the blood type O (Table 3) . Dose-response relationship between the ACE activity and genotypes of ACE and ABO The mean ACE activity among subjects with G allele of ACE-rs4343 increased by 3.5 IU l À1 per copy of the allele. The ABO-rs8176746 showed the same additive effects on ACE activity and increment was about 1.4-2.3 IU l À1 per copy of the A allele. Following a recessive model, the mean ACE activity among subjects with the CC genotype at ABOrs495828 was B3 IU l À1 higher than the CA or AA genotype subjects (Table 4) .
Differential blood pressure trends by the number of ACE-activityraising alleles/genotypes between ACEI-only users and subjects no taking medication The average levels of SBP and DBP (P ¼ 0.8875 and 0.9511, respectively) were not significantly different between ACEI users and nonusers without stratifying on ACE-activity-raising alleles status. The mean ACE activity among subjects using ACEI alone was significantly lower than the subjects without taking antihypertensive medication (P ¼ 1.98 Â 10 À9 ). The total number of the ACE-activityraising alleles or genotypes, including those from the ACErs4343, the ABO-rs495828 and rs8176746, was calculated for each individual. A score of 1 was given to G allele of ACErs4343, CC genotype of ABO-rs495858 and CA or AA genotype of ABO-rs8176746. The mean ACE activity was found increasing linearly with the total number of these alleles/genotypes (Table 4 ; P-value for trend ¼ 3.47 Â 10
À53
). The differences of the mean ACE activity and SBP/DBP levels between the subjects taking ACEI-alone and those not taking antihypertensive medication increased with the increasing number of ACE-activity-raising alleles or genotypes ( Figure 2) . The P-value corresponding to medication (0, 1) Â genetic score interaction term was 0.0448 for ACE activity, 0.0295 for SBP and 0.1241 for DBP.
Discussion
We performed a two-stage GWAS to search the genes/loci that affect the ACE activity. In the process, we identified Global P-values were obtained from the GLM procedure with adjustment for age, gender (0, 1) and ACEI intake (0, 1). three SNPs in loci that harbor two candidate genes, including an SNP in the ACE structural gene, and two in the ABO gene. The last two were not previously found directly linked to the ACE activity, although association between the ACE activity and the ABO blood type (not ABO genotype) was noted for the Caucasian subjects. 20 We further demonstrated a potential differential blood pressure response to ACEI in subjects with varied numbers of ACEactivity-raising alleles.
Our findings of the ABO gene on the chromosome 9 is within 1 cM of our previously identified linkage peak at 149.4 cM of chromosome 9 obtained by a genome-wide linkage family survey. 17 This is a unique example showing that two independent research designs, an individual casecontrol study and a family-based genetic analysis, revealed the same novel locus near or at the ABO gene, in addition to the ACE gene. The ABO encodes the glycosyltransferase that transfers the monosaccharides to the cell-surface H antigens. There are three major isoforms: A, B and O. Each has its own specificity and activity. The glycosylation of the H antigens of the ABO groups A and B is catalyzed by the glycosyltransferases A (for N-acetyl galactosamine) and B (for D-galactose), respectively. The O allele does not produce an active enzyme. 21 The ABO histo-blood group phenotypes have been found associated with a risk of infectious diseases, various cancers, blood pressure 22 and vascular diseases. 23 Of particular interest is the association of O histo-blood groups with a reduced risk of myocardial infarction, peripheral vascular disease, stroke and venous thromboembolism. 24 These findings are only partially explained by the lower levels of factor VIIIc and Willebrand factor in the O blood types as compared with other blood types. 25 The exact mechanism is not entirely understood.
Our results show that the blood group may affect on blood pressure and cardiovascular diseases by influencing the ACE activity. Very important is the role of carbohydrate processing in the ACE conformation and function. 26 Because the ACE molecules are carriers of the ABO antigens, oligosaccharide moieties on ABO antigens being bound covalently to the ACE molecules may impact the aqueous solubility of the ACE and its susceptibility to protease resulting in the varied degree of active ACE enzyme released. 20 In the early 1980s, a Veterans Affairs Cooperative Trial indicated that the responses to antihypertensive drug therapy varied ethnically. 27 Our findings could contribute to the understanding of the pharmacogenetics of ACErelated drugs. Although no pharmacogenetic association between ACE insertion/deletion genotype and blood pressure response was identified in a large-scale clinical trial study, 28 it is shown by us in people with a relatively high number of ACE-activity-raising alleles/genotypes, those who take the ACEI show a lower mean blood pressure values than those who do not. Conversely, in people having no such alleles, disadvantageously higher mean blood pressure values are observed in those taking ACEI than those not. It remained possible that blood pressure response to ACEI may be associated with serum ACE activity, which is determined by multiple genetic loci. If we simply focused on ACE-rs4343 genotype alone, our study could not find any its modifying Difference of the mean SBP between the subjects taking ACE I and the subjects without medication
Difference of the mean DBP between the subjects taking ACE I and the subjects without medication
Difference of the mean ACE activity between the subjects taking ACE I and the subjects without medication Figure 2 Mean SBP/DBP difference between subjects with antihypertensive medication and those without it by the number of ACE-activity-raising alleles. The GLM was used to compare the interaction between medication status (0, 1) and the number of ACE-activity-raising alleles (0-4). Subjects taking more than one medication were excluded from the study. ACE, angiotensin-converting enzyme; GLM, general linear model; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACEI, ACE inhibitors.
effect of blood pressure response to ACEI treatment (data not shown) as the Genetics of Hypertension-Associated Treatment study. 28 Because ACEI exerts its blood-pressurelowering effect by reducing ACE activity, 29, 30 it is reasonable to observe that the ACEI is more effective for the subjects with higher ACE activity and may be deleterious for those with low ACE activity. If our findings can be substantiated by a clinical trial, either the number of ACE-activity-raising alleles/genotypes present in the ACE, and ABO genes or ACE activity may be used as a reliable predictor of the SBP response to the ACEI, which may help determine whether ACEI is the choice of antihypertensives for given individual patients.
Considerable information on blood pressure regulation is available. Yet only a quantum of blood pressure variation is observed to have attributed to the known candidate genes. To date, searches for high-impact hypertension susceptibility genes or loci are unsatisfactory. Even the recent impressive GWAS 1 do not score a breakthrough. No SNP has been identified to be strongly associated with hypertension. The Family Blood Pressure Program could not replicate any hypertensive associations for the six top-ranking SNPs revealed by Wellcome Trust Case Control Consortium. 31 No doubt, complexity of blood pressure regulation is related to a number of phenomena. They include the possible multiple pleiotropic variants of low penetrance, genetic epistasis, ethnic diversity, phenotypic heterogeneity and uncontrolled environmental factors. All add to the difficulty of analysis. One of the state-of-art approaches to alleviate, but by no means eliminate, such a difficulty is to undertake a gigantic scale of sampling, aiming at identifying the variants with only small-to-moderate increases in risk. In the meantime, we can also address ourselves to relatively homogeneous subphenotypes of hypertension. Our GWAS study on the ACE activity accords with the latter approach and illustrates that it may help to reduce the dimension of the hypertension heterogeneity effectively.
Our study is not free of shortcomings. First, this study was conducted in hypertensive subjects, although a successful small-scale confirmation study has been illustrated in normotensive subjects. There might still be concerns to apply the results of our study to the general population without further replication studies. Second, the use of hypertensive drug was based on the self-report in each case. This could conceivably give rise to a misclassification and an underestimate of the true magnitude of genotype-drug response association. Third, the phenomena of differential blood pressure values in some people with high ACE activity genotypes and in those without such genotypes are still to be studied in depth. They must be substantiated by means of the clinical trial data. This paper shows that the ACE activity is significantly allied with genetic variations at the ACE, and ABO loci in hypertensive subjects. Inasmuch as we know, ours is the first attempt to have shown that ABO gene may have a vital role in regulating the ACE activity. These findings might help explain some of controversial results regarding the relation between ACE activity, blood pressure regulation and cardiovascular diseases. If our findings can be substantiated by a clinical trial, this information might be applied to fine-tune the medication strategy for hypertension, for example, directing ACEI to those with genetic susceptibility to high ACE activity. Our study provides an example on how GWAS finding on a quantitative trait, ACE activity, is implicated in pharmacogenomics and may potentially lead to changing the customary trial-and-error practice in hypertension treatment.
